RBC
CRSP icon

Romano Brothers & Co’s CRISPR Therapeutics CRSP Stock Holding History

Romano Brothers & Co’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-204
Closed -$8.29K – 441
2022
Q4 		$8.29K Buy
+204
New +$10.8K ﹤0.01% 756

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Romano Brothers & Co's CRSP Position: Q1 2023 in Review

Romano Brothers & Co sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 204 shares — an estimated $8.29K sold.

Romano Brothers & Co first reported a position in CRSP in Q4 2022 and held it in 1 quarter. The position peaked at $8.29K in Q4 2022. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

  • Romano Brothers & Co reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 204 CRISPR Therapeutics shares in Q1 2023, an estimated $8.29K.
  • Romano Brothers & Co first reported a position in CRISPR Therapeutics in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's CRISPR Therapeutics position peaked at $8.29K in Q4 2022.
  • 381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.